National Health Insurance Service Ilsan Hospital Researcher Publishes Findings in Dyslipidemias (Intensity of statin therapy and primary prevention of cardiovascular in Korean patients with dyslipidemia): Nutritional and Metabolic Diseases and Conditions – Dyslipidemias

2024 MAR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- Investigators publish new report on dyslipidemias. According to news reporting out of Goyang, South Korea, by NewsRx editors, research stated, “This study aimed to investigate the association between the intensity of statin therapy and the development of cardiovascular disease (CVD) and diabetes in individuals without prior diabetes who were being treated for dyslipidemia with statins for the primary prevention of CVD, using the National Health Insurance Service-Health Screening database.”

The news editors obtained a quote from the research from National Health Insurance Service Ilsan Hospital: “The database is a longitudinal cohort study of Korean men and women 40 years of age or older who underwent comprehensive biannual screening health examinations by Korean National Health Insurance Service from January 1, 2002, to December 31, 2015. We included patients in the health screening checkup cohort who underwent health checkups in 2009 and 2010.The primary outcome was the occurrence of a first major cardiovascular or cerebrovascular event, new-onset diabetes. A total of 20,322 participants without prior diabetes at baseline from 2009 to 2015 were followed up for a mean duration of 81.2 ± 6.6 months. The mean age of all participants at baseline was 59.2 ± 8.4 years and 43.0% of them were male. Their index low lipoprotein cholesterol level was 130.4 ± mg/dL, the mean duration of taking statins was 337.4 ± 52.3 days, and 93.9% of them had been taking moderate-intensity statins. At that time, a total of 641 diabetes cases occurred, 41 from using low-intensity statins, 588 from moderate-intensity statins, and 11 from high-intensity statins.”

According to the news editors, the research concluded: “The results indicated no significant differences in the incidence of death, CVD death, or CVD among those in the strong statin group compared with the reference groups. While statin treatment for the primary prevention of CVD in patients with dyslipidemia showed a subtle difference in the incidence of diabetes, there was no difference in the occurrence of CVD or CVD death according to statin intensity.”

For more information on this research see: Intensity of statin therapy and primary prevention of cardiovascular in Korean patients with dyslipidemia. Medicine, 2024,103(11). (Medicine - http://journals.lww.com/md-journal). The publisher for Medicine is Ovid Technologies (Wolters Kluwer Health).

A free version of this journal article is available at https://doi.org/10.1097/md.0000000000037536.

Our news journalists report that additional information may be obtained by contacting Sun Ok Song, Division of Endocrinology and Metabolism, National Health Insurance Service Ilsan Hospital, Goyang, South Korea. Additional authors for this research include Min Jin Kang, Sunghwan Suh.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the authors of this research: Sun Ok Song (http://orcid.org/0000-0003-4829-3407), Sunghwan Suh (http://orcid.org/0000-0001-6865-966X). Our reports deliver fact-based news of research and discoveries from around the world.